Plasminogen activator inhibitor-1 modulates adipocyte differentiation

Am J Physiol Endocrinol Metab. 2006 Jan;290(1):E103-E113. doi: 10.1152/ajpendo.00605.2004. Epub 2005 Sep 6.

Abstract

Increased plasminogen activator inhibitor-1 (PAI-1) is linked to obesity and insulin resistance. However, the functional role of PAI-1 in adipocytes is unknown. This study was designed to investigate effects and underlying mechanisms of PAI-1 on glucose uptake in adipocytes and on adipocyte differentiation. Using primary cultured adipocytes from PAI-1(+/+) and PAI-1(-/-) mice, we found that PAI-1 deficiency promoted adipocyte differentiation, enhanced basal and insulin-stimulated glucose uptake, and protected against tumor necrosis factor-alpha-induced adipocyte dedifferentiation and insulin resistance. These beneficial effects were associated with upregulated glucose transporter 4 at basal and insulin-stimulated states and upregulated peroxisome proliferator-activated receptor-gamma (PPARgamma) and adiponectin along with downregulated resistin mRNA in differentiated PAI-1(-/-) vs. PAI-1(+/+) adipocytes. Similarly, inhibition of PAI-1 with a neutralizing anti-PAI-1 antibody in differentiated 3T3-L1 adipocytes further promoted adipocyte differentiation and glucose uptake, which was associated with increased expression of transcription factors PPARgamma, CCAAT enhancer-binding protein-alpha (C/EBPalpha), and the adipocyte-selective fatty acid-binding protein aP2, thus mimicking the phenotype in PAI-1(-/-) primary adipocytes. Conversely, overexpression of PAI-1 by adenovirus-mediated gene transfer in 3T3-L1 adipocytes inhibited differentiation and reduced PPARgamma, C/EBPalpha, and aP2 expression. This was also associated with a decrease in urokinase-type plasminogen activator mRNA expression, decreased plasmin activity, and increased collagen I mRNA expression. Collectively, these results indicate that absence or inhibition of PAI-1 in adipocytes protects against insulin resistance by promoting glucose uptake and adipocyte differentiation via increased PPARgamma expression. We postulate that these PAI-1 effects on adipocytes may, at least in part, be mediated via modulation of plasmin activity and extracellular matrix components.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 3T3-L1 Cells
  • Adipocytes / cytology*
  • Adipocytes / drug effects
  • Adipocytes / metabolism
  • Adiponectin / genetics
  • Animals
  • Antibodies, Monoclonal / pharmacology
  • CCAAT-Enhancer-Binding Protein-alpha / metabolism
  • Cell Differentiation / drug effects
  • Cell Differentiation / genetics
  • Cell Differentiation / physiology*
  • Collagen Type I / genetics
  • Fatty Acid-Binding Proteins / metabolism
  • Fibrinolysin / metabolism
  • Gene Expression / genetics
  • Glucose / metabolism
  • Glucose / pharmacokinetics
  • Glucose Transporter Type 4 / metabolism
  • Insulin / pharmacology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • PPAR gamma / genetics
  • PPAR gamma / metabolism
  • Plasminogen Activator Inhibitor 1 / genetics
  • Plasminogen Activator Inhibitor 1 / metabolism
  • Plasminogen Activator Inhibitor 1 / physiology*
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Resistin / genetics
  • Tumor Necrosis Factor-alpha / pharmacology
  • Urokinase-Type Plasminogen Activator / genetics

Substances

  • Adiponectin
  • Antibodies, Monoclonal
  • CCAAT-Enhancer-Binding Protein-alpha
  • Collagen Type I
  • Fatty Acid-Binding Proteins
  • Glucose Transporter Type 4
  • Insulin
  • PPAR gamma
  • Plasminogen Activator Inhibitor 1
  • RNA, Messenger
  • Resistin
  • SERPINE1 protein, human
  • Slc2a4 protein, mouse
  • Tumor Necrosis Factor-alpha
  • Fibrinolysin
  • Urokinase-Type Plasminogen Activator
  • Glucose